MiniMed Flex™ Now Available to Medicare and Medicare Advantage Beneficiaries
Rhea-AI Summary
MiniMed (Nasdaq: MMED) announced that Medicare and Medicare Advantage beneficiaries in the U.S. now have access to the MiniMed Flex™ insulin pump system with its latest sensor portfolio. This expansion makes MiniMed’s smallest and only app-controlled pump available to more people living with diabetes.
MiniMed Flex™ is about half the size of previous MiniMed pumps, roughly the size of two stacked insulin vials, yet holds 300 units of insulin. Powered by the same SmartGuard™ technology used in the MiniMed™ 780G system, it automatically adjusts insulin delivery every five minutes. According to MiniMed, real-world data in Medicare users of MiniMed™ 780G showed glycemic outcomes exceeding American Diabetes Association targets. In the U.S., MiniMed Flex™ is available with the Simplera Sync™ sensor and is expected to be available with Abbott’s Instinct sensor later this summer.
Positive
- None.
Negative
- None.
News Market Reaction – MMED
In the Jul 22 session, MMED declined 2.22%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 20 | Earnings date notice | Neutral | +1.1% | Company scheduled fiscal 2027 first-quarter results for September 1, 2026. |
| Jun 29 | Board appointments | Positive | +4.5% | Alcon CEO David Endicott and Linnea Burman joined the expanded board. |
| Jun 23 | Sensor portfolio launch | Positive | -3.4% | MiniMed launched Abbott-made Instinct sensors in Europe with expanded sensor choice. |
| Jun 17 | U.S. pump launch | Positive | -3.6% | MiniMed commercially launched its smallest app-controlled insulin pump in the United States. |
| Jun 03 | Abbott sensor agreement | Positive | +15.9% | MiniMed expanded its agreement with Abbott for integrated glucose-ketone sensors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
MiniMed's recent news reactions were mixed, with positive announcements followed by both gains and declines.
Key Terms
real-world evidence medical
glycemic targets medical
cgms medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MiniMed Flex™ is about half the size* of previous MiniMed pumps and roughly the size of two stacked insulin vials, offering a sleek, compact design while still holding 300 units of insulin. Powered by the same SmartGuard™ technology of the MiniMed™ 780G system, this system automatically adjusts insulin delivery every five minutes, day and night.
The expanded availability is especially meaningful given the strong outcomes Medicare beneficiaries have achieved with the same SmartGuard™ technology that powers MiniMed Flex™. Real-world evidence presented at the 86th American Diabetes Association Scientific Sessions found that Medicare beneficiaries using the MiniMed™ 780G system exceeded ADA-recommended glycemic targets, highlighting the potential impact of making this technology available to more people.1**
"Managing diabetes is relentless — and no one should have to do it without the best tools available," said Que Dallara, chief executive officer, MiniMed. "Ensuring Medicare access to MiniMed Flex™ is about making sure more people can benefit from technology that fits into daily life and takes some of the burden off their shoulders. Everyone deserves that regardless of age."
"The biggest difference with MiniMed Flex is that diabetes doesn't demand my attention as often," said Charlie Saxe, MiniMed Flex™ User. "The pump stays tucked away, I manage everything through the app, and the system works quietly in the background. It gives me more confidence and lets me focus on my life instead of constantly thinking about my diabetes."
In the
For more information, reimbursement support, or to order the MiniMed Flex™ system, visit www.minimed.com/flex.
About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.
Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
References
*Pump dimensions on File – IFU Labeling. Overall size related to volume.
**Due to inherent real-world data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.
- McVean J., et al. Medicare Beneficiaries with Type 1 and Type 2 Diabetes Using the MiniMed™ 780G System Exceeds Glycemic Targets. Presented at: 86th American Diabetes Association Scientific Sessions; June 5-8, 2026; New Orleans, LA. Poster 1863-P.
View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-flex-now-available-to-medicare-and-medicare-advantage-beneficiaries-302831504.html
SOURCE MiniMed